LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.26% | 62.72% | 74.23% | 77.07% | 57.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.26% | 62.72% | 74.23% | 77.07% | 57.17% |
| Cost of Revenue | 46.33% | 40.66% | 45.69% | 37.56% | 19.43% |
| Gross Profit | 103.41% | 152.03% | 219.08% | 1,132.14% | 2,089.53% |
| SG&A Expenses | 31.86% | 44.08% | -12.26% | -10.84% | -23.72% |
| Depreciation & Amortization | 4.84% | 4.84% | 4.84% | -297.15% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.46% | 40.84% | 21.21% | 14.79% | -0.69% |
| Operating Income | 191.46% | 132.55% | 108.09% | 87.33% | 83.79% |
| Income Before Tax | 219.63% | 196.73% | 138.00% | 76.16% | 74.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 217.92% | 195.29% | 137.43% | 76.16% | 74.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 217.92% | 195.29% | 137.43% | 76.16% | 74.28% |
| EBIT | 191.46% | 132.55% | 108.09% | 87.33% | 83.79% |
| EBITDA | 14,037.67% | 468.32% | 150.40% | 108.02% | 100.36% |
| EPS Basic | 187.24% | 166.45% | 122.58% | 80.90% | 78.81% |
| Normalized Basic EPS | 64.47% | 66.31% | 81.11% | 71.18% | 70.88% |
| EPS Diluted | 167.72% | 152.77% | 119.37% | 77.58% | 75.15% |
| Normalized Diluted EPS | 64.47% | 66.31% | 81.11% | 71.18% | 70.88% |
| Average Basic Shares Outstanding | 30.08% | 36.29% | 32.79% | 26.40% | 22.89% |
| Average Diluted Shares Outstanding | 30.10% | 36.39% | 32.89% | 26.50% | 22.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |